Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival

Pigment Cell and Melanoma Research

Volumn 21, Issue 5, 2008, Pages 534-544

  Cartlidge, Robert A ^a   Thomas, G R ^a   Cagnol, Sebastien ^a   Jong, Kimberly A ^a   Molton, Sarah A ^a   Finch, Andrew J ^a   McMahon, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Bcl 2; Bim; BRAF; Melanoma

Indexed keywords

B RAF KINASE; BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEASOME; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOCYTES; MELANOMA; MEMBRANE PROTEINS; MICE; MITOCHONDRIA; POINT MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 52149107116     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00491.x     Document Type: Article

References (49)

1. Allan, L.A., Morrice, N., Brady, S., Magee, G., Pathak, S. Clarke, P.R. (2003). Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat. Cell Biol. 5, 647 654.
2. Baccarini, M. (2002). An old kinase on a new path: Raf and apoptosis. Cell Death Differ. 9, 783 785.
3. Boisvert-Adamo, K. Aplin, A.E. (2008). Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27, 3301 3312.
4. Bouillet, P., Cory, S., Zhang, L.C., Strasser, A. Adams, J.M. (2001). Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev. Cell 1, 645 653.
5. Cai, B., Chang, S.H., Becker, E.B., Bonni, A. Xai, Z. (2006). p38 MAP kinase mediates apoptosis through phosphorylation of BIM-EL at Ser65. J. Biol. Chem. 281, 25215 25222.
6. Chin, L., Merlino, G. DePinho, R.A. (1998). Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12, 3467 3481.
7. Christensen, C. Guldberg, P. (2005). Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 24, 6292 6302.
8. Collins, N.L., Reginato, M.J., Paulus, J.K., Sgroi, D.C., Labaer, J. Brugge, J.S. (2005). G1/S cell cycle arrest provides anoikis resistance through ERK-mediated Bim suppression. Mol. Cell. Biol. 25, 5282 5291.
9. Dai, D.L., Wang, Y., Liu, M., Martinka, M. Li, G. (2008). Bim expression is reduced in human cutaneous melanomas. J. Invest. Dermatol., 128, 403 407.
10. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
11. Day, C.L., Puthalakath, H., Skea, G., Strasser, A., Barsukov, I., Lian, L.Y., Huang, D.C. Hinds, M.G. (2004). Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. Biochem. J. 377, 597 605.
12. Erhardt, P., Schremser, E.J. Cooper, G.M. (1999). B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 19, 5308 5315.
13. Ewings, K.E., Wiggins, C.M. Cook, S.J. (2007). Bim and the pro-survival Bcl-2 proteins; opposites attract, ERK repels. Cell Cycle 6, 2236 2240.
14. Goel, V.K., Lazar, A.J., Warneke, C.L., Redston, M.S. Haluska, F.G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154 160.
15. Gray-Schopfer, V., Wellbrock, C. Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851 857.
16. Gysin, S., Lee, S.H., Dean, N.M. McMahon, M. (2005). Pharmacologic inhibition of RAF→MEK→ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 65, 4870 4880.
17. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M. Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198 5202.
18. Ley, R.K., Balmanno, K., Hadfield, K., Weston, C. Cook, S.J. (2003). Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 278, 18811 18816.
19. Ley, R., Ewings, K.E., Hadfield, K. Cook, S.J. (2005). Regulatory phosphorylaiton of Bim: sorting out the ERK from the JNK. Cell Death Diff. 12, 1008 1014.
20. Liu, J., Suresh Kumar, K.G., Yu, D., Molton, S.A., McMahon, M., Herlyn, M., Thomas-Tikhonenko, A. Fuchs, S.Y. (2007). Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene 26, 1954 1958.
21. Marani, M., Hancock, D., Lopes, R., Tenev, T., Downward, J. Lemoine, N.R. (2004). Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23, 2431 2441.
22. McCarthy, S.A., Samuels, M.L., Pritchard, C.A., Abraham, J.A. McMahon, M. (1995). Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev. 9, 1953 1964.
23. Mohammad, R., Giri, A. Goustin, A.S. (2008). Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent Patents Anticancer Drug Discov. 3, 20 30.
24. Morgenstern, J.P. Land, H. (1990a). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587 3596.
25. Morgenstern, J.P. Land, H. (1990b). A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res. 18, 1068.
26. O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M., Cory, S. Huang, D.C. (1998). Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17, 384 395.
27. Patton, E.E., Widlund, H.R., Kutok, J.L. et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249 254.
28. Pear, W.S., Nolan, G.P., Scott, M.L. Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl Acad. Sci. U. S. A. 90, 8392 8396.
29. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19 20.
30. Ramjaun, A.R., Tomlinson, S., Eddaoudi, A. Downward, J. (2007). Upregulation of two BH3-only proteins, Bmf and Bim, during TGFbeta-induced apoptosis. Oncogene 26, 970 981.
31. Reginato, M.J., Mills, K.R., Paulus, J.K., Lynch, D.K., Sgroi, D.C., Debnath, J., Muthuswamy, S.K. Brugge, J.S. (2003). Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 5, 733 740.
32. Richardson, P.G., Mitsiades, C., Hideshima, T. Anderson, K.C. (2006). Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57, 33 47.
33. Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M. McCormick, F. (2000). Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103, 321 330.
34. Saelens, X., Festjens, N., Vande Walle, L., van Gurp, M., van Loo, G. Vandenabeele, P. (2004). Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861 2874.
35. Samuels, M.L., Weber, M.J., Bishop, J.M. McMahon, M. (1993). Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol. Cell. Biol. 13, 6241 6252.
36. Schulze, A.K., Lehmann, K., Jefferies, H.B., McMahon, M. Downward, J. (2001). Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev., 15, 981 994.
37. Sebolt-Leopold, J.S., Dudley, D.T., Herrera, R. et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5, 810 816.
38. Sharma, A., Trivedi, N.R., Zimmerman, M.A., Tuveson, D.A., Smith, C.D. Robertson, G.P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412 2421.
39. Soengas, M.S. Lowe, S.W. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138 3151.
40. Thompson, N. Lyons, J. (2005). Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 5, 350 356.
41. Tsai, J., Lee, J.T., Wang, W. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U. S. A. 105, 3041 3046.
42. Tsao, H., Goel, V., Wu, H., Yang, G. Haluska, F.G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122, 337 341.
43. Veis, D.J., Sorenson, C.M., Shutter, J.R. Korsmeyer, S.J. (1993). Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75, 229 240.
44. Verhaegen, M., Bauer, J.A., Martin de la Vega, C. et al. (2006). A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 66, 11348 11359.
45. Wan, P.T., Garnett, M.J., Roe, S.M. et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855 867.
46. Wang, Y.F., Jiang, C.C., Kieja, K.A., Gillespie, S., Zhang, X.D. Hersey, P. (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim and Mcl-1. Clin. Cancer Res. 13, 4934 4942.
47. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C.J. Marais, R. (2004). V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338 2342.
48. Woods, D., Cherwinski, H., Venetsanakos, E., Bhat, A., Gysin, S., Humbert, M., Bray, P.F., Saylor, V.L. McMahon, M. (2001). Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol. Cell. Biol. 21, 3192 3205.
49. Youle, R.J. Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell. Biol. 9, 47 59.